Variable fitness effects of bacteriophage resistance mutations in Escherichia coli: implications for phage therapy
Journal of Virology · 22.10.2024 · 98 (10)
DOI: 10.1128/jvi.01113-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, erschienen am 22.10.2024. Verfasst von Baptiste Gaborieau und 6 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité, INSERM UMR1137, IAME, Paris, France. Hauptthemen laut MEDLINE: Mutation, Phage Therapy, Escherichia coli, Escherichia coli Infections. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), Agence Nationale de la Recherche (ANR), Fondation pour la Recherche Médicale (FRM).
Abstract (Originalsprache)
Bacteria exposed to bactericidal treatment, such as antibiotics or bacteriophages (phages), often develop resistance. While phage therapy is proposed as a solution to the antibiotic resistance crisis, the bacterial resistance emerging during phage therapy remains poorly characterized. In this study, we examined a large population of phage-resistant extra-intestinal pathogenic Escherichia coli 536 clones that emerged from both in vitro (non-limited liquid medium) and in vivo (murine pneumonia) conditions. Genome sequencing uncovered a convergent mutational pattern in phage resistance mechanisms under both conditions, particularly targeting two cell-wall components, the K15 capsule and the lipopolysaccharide (LPS). This suggests that their identification in vivo could be predicted from in vitro assays. Phage-resistant clones exhibited a wide range of fitness according to in vitro tests, growth rate, and resistance to amoeba grazing, which could not distinguish between the K15 capsule and LPS mutants. In contrast, K15 capsule mutants retained virulence comparable to the wild-type strain, whereas LPS mutants showed significant attenuation in the murine pneumonia model. Additionally, we observed that resistance to the therapeutic phage through a nonspecific mechanism, such as capsule overproduction, did not systematically lead to co-resistance to other phages that were initially capable or incapable of infecting the wild-type strain. Our findings highlight the importance of incorporating a diverse range of phages in the design of therapeutic cocktails to target potential future phage-resistant clones effectively. IMPORTANCE This study isolated more than 50 phage-resistant mutants from both in vitro and in vivo conditions, exposing an extra-intestinal pathogenic Escherichia coli strain to a single virulent phage. The characterization of these clones revealed several key findings: (1) mutations occurring during phage treatment affect the same pathways as those identified in vitro ; (2) the resistance mechanisms are associated with the modification of two cell-wall components, with one involving receptor deletion (phage-specific mechanism) and the other, less frequent, involving receptor masking (phage-nonspecific mechanism); (3) an in vivo virulence assay demonstrated that the absence of the receptor abolishes virulence while masking the receptor preserves it; and (4) clones with a resistance mechanism nonspecific to a particular phage can remain susceptible to other phages. This supports the idea of incorporating diverse phages into therapeutic cocktails designed to collectively target both wild-type and phage-resistant strains, including those with resistance mechanisms nonspecific to a phage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université Paris Cité, INSERM UMR1137, IAME, Paris, France.
- Institut Pasteur, Université Paris Cité, CNRS UMR6047, Bacteriophage Bacterium Host, Paris, France.
- APHP, Hôpital Louis Mourier, DMU ESPRIT, Service de Médecine Intensive Réanimation, Colombes, France.
- Institut de Biologie de l'ENS (IBENS), École Normale Supérieure CNRS UMR8197, Paris, France.
- APHP, Hôpital Bichat, Service de Génétique Moléculaire, Paris, France.
ORCID-Profile: Baptiste Gaborieau, Erick Denamur, Jean-Damien Ricard, Laurent Debarbieux
Förderung
- Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM)
- Agence Nationale de la Recherche (ANR)
- Fondation pour la Recherche Médicale (FRM)
- Amicale des Anciens Internes des Hôpitaux de Paris
- Institut Pasteur
Zitieren
APA
Gaborieau, B., Delattre, R., Adiba, S., Clermont, O., Denamur, E., Ricard, J. D., & Debarbieux, L. (2024). Variable fitness effects of bacteriophage resistance mutations in Escherichia coli: implications for phage therapy. Journal of Virology, 98(10). https://doi.org/10.1128/jvi.01113-24
Vancouver
Gaborieau B, Delattre R, Adiba S, Clermont O, Denamur E, Ricard JD, et al. Variable fitness effects of bacteriophage resistance mutations in Escherichia coli: implications for phage therapy. Journal of Virology. 2024;98(10). doi:10.1128/jvi.01113-24
BibTeX
@article{Gaborieau2024,
author = {Gaborieau, Baptiste and Delattre, Raphaëlle and Adiba, Sandrine and Clermont, Olivier and Denamur, Erick and Ricard, Jean-Damien and Debarbieux, Laurent},
title = {Variable fitness effects of bacteriophage resistance mutations in Escherichia coli: implications for phage therapy},
journal = {Journal of Virology},
year = {2024},
volume = {98},
number = {10},
doi = {10.1128/jvi.01113-24}
}
EUVIMED